[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]

April 2019 - April 2016

Decade

Year

Issue

July 2017, Vol 2, No. 7, Pages 709-824

In This Issue of JAMA Cardiology

Highlights

Abstract Full Text
free access
JAMA Cardiol. 2017;2(7):709. doi:10.1001/jamacardio.2016.3654
Original Investigation

Association of US Centers for Medicare and Medicaid Services Hospital 30-Day Risk-Standardized Readmission Metric With Care Quality and Outcomes After Acute Myocardial Infarction: Findings From the National Cardiovascular Data Registry/Acute Coronary Treatment and Intervention Outcomes Network Registry–Get With the Guidelines

Abstract Full Text
free access has audio
JAMA Cardiol. 2017;2(7):723-731. doi:10.1001/jamacardio.2017.1143

This analysis evaluates the association between excess readmission ratio for myocardial infarction with in-hospital process of care measures and 1-year clinical outcomes during the first cycle of the Centers for Medicare and Medicaid Services Hospital Readmissions Reduction Program.

Association Between Hospital Volume and 30-Day Readmissions Following Transcatheter Aortic Valve Replacement

Abstract Full Text
free access
JAMA Cardiol. 2017;2(7):732-741. doi:10.1001/jamacardio.2017.1630

This observational study assesses the association between hospital transcatheter aortic valve replacement volume and 30-day readmission among patients with severe aortic stenosis.

Association of Transcatheter Aortic Valve Replacement With 30-Day Renal Function and 1-Year Outcomes Among Patients Presenting With Compromised Baseline Renal Function: Experience From the PARTNER 1 Trial and Registry

Abstract Full Text
free access
JAMA Cardiol. 2017;2(7):742-749. doi:10.1001/jamacardio.2017.1220

This cohort substudy of a clinical trial examines renal functions and outcomes of high-surgical-risk or inoperable patients with severe symptomatic aortic stenosis undergoing a transcatheter aortic valve replacement who had impaired baseline estimated glomerular filtration rates at 30 days.

Accuracy of Medical Claims for Identifying Cardiovascular and Bleeding Events After Myocardial Infarction : A Secondary Analysis of the TRANSLATE-ACS Study

Abstract Full Text
free access has audio
JAMA Cardiol. 2017;2(7):750-757. doi:10.1001/jamacardio.2017.1460

This secondary analysis of a clinical trial analyzes medical claims and records of patients enrolled in the TRANSLATE-ACS study to determine the accuracy of claims data over physician adjudication in detecting cardiovascular events.

Efficacy of Flecainide in the Treatment of Catecholaminergic Polymorphic Ventricular Tachycardia: A Randomized Clinical Trial

Abstract Full Text
free access
JAMA Cardiol. 2017;2(7):759-766. doi:10.1001/jamacardio.2017.1320

This randomized clinical trial determines whether flecainide dosed to therapeutic levels and added to β-blocker therapy is superior to β-blocker therapy alone for the prevention of exercise-induced arrhythmias in catecholaminergic polymorphic ventricular tachycardia.

Association of Implantable Cardioverter Defibrillators With Survival in Patients With and Without Improved Ejection Fraction: Secondary Analysis of the Sudden Cardiac Death in Heart Failure Trial

Abstract Full Text
free access
JAMA Cardiol. 2017;2(7):767-774. doi:10.1001/jamacardio.2017.1413

This secondary analysis of data from the Sudden Cardiac Death in Heart Failure Trial examines the efficacy of implantable cardioverter defibrillator therapy in reducing risk of all-cause mortality and sudden cardiac death among patients with or without an improvement in ejection fraction to >35% during follow-up.

Systolic Blood Pressure Reduction and Risk of Cardiovascular Disease and Mortality: A Systematic Review and Network Meta-analysis

Abstract Full Text
free access
JAMA Cardiol. 2017;2(7):775-781. doi:10.1001/jamacardio.2017.1421

This systematic review and network meta-analysis assesses the association of mean achieved systolic blood pressure levels with the risk of cardiovascular disease and all-cause mortality in adults with hypertension treated with antihypertensive therapy.

Income Disparities in Absolute Cardiovascular Risk and Cardiovascular Risk Factors in the United States, 1999-2014

Abstract Full Text
free access
JAMA Cardiol. 2017;2(7):782-790. doi:10.1001/jamacardio.2017.1658

This cross-sectional analysis uses NHANES data to assess temporal trends in 10-year predicted absolute cardiovascular risk and cardiovascular risk factors among US adults in different socioeconomic strata.

Brief Report

One-Year Mortality for Bivalirudin vs Heparins Plus Optional Glycoprotein IIb/IIIa Inhibitor Treatment Started in the Ambulance for ST-Segment Elevation Myocardial Infarction: A Secondary Analysis of the EUROMAX Randomized Clinical Trial

Abstract Full Text
free access
JAMA Cardiol. 2017;2(7):791-796. doi:10.1001/jamacardio.2016.5975

This secondary analysis of the EUROMAX randomized clinical trial assesses the effect of bivalirudin vs heparin plus optional glycoprotein IIb/IIIa inhibitors on 1-year mortality in patients with ST-segment elevation myocardial infarction.

Mortality, Length of Stay, and Cost Implications of Procedural Bleeding After Percutaneous Interventions Using Large-Bore Catheters

Abstract Full Text
free access
JAMA Cardiol. 2017;2(7):798-802. doi:10.1001/jamacardio.2017.0265

This cohort study uses HCUP National Inpatient Sample data to assess the bleeding complications following endovascular procedures that use large-bore catheters and the association with in-hospital mortality risk, length of stay, and cost.

Research Letter

Trends in Cardiovascular Health of US Adults by Income, 2005-2014

Abstract Full Text
free access
JAMA Cardiol. 2017;2(7):814-816. doi:10.1001/jamacardio.2017.1654

This study assesses national trends in cardiovascular risk factors by income level among adults aged 25 years and older using data from the National Health and Nutrition Examination Surveys.

Viewpoint

Coverage of Magnetic Resonance Imaging for Patients With Cardiac Devices: Improving the Coverage With Evidence Development Program

Abstract Full Text
JAMA Cardiol. 2017;2(7):711-712. doi:10.1001/jamacardio.2017.1674

This Viewpoint discusses Medicare reimbursement for magnetic resonance imaging performed for patients with cardiac implantable electrical devices.

The Management of Antiplatelet and Antithrombotic Regimens in Patients With Mechanical Valves Undergoing Percutaneous Coronary Intervention: A Forgotten Cohort?

Abstract Full Text
JAMA Cardiol. 2017;2(7):713-714. doi:10.1001/jamacardio.2017.0930

This Viewpoint examines and outlines future directions for the management of antiplatelet and antithrombotic regimens in patients with mechanical valves undergoing percutaneous coronary intervention.

From the Heart

Balancing Motherhood, Career, and Medicine

Abstract Full Text
JAMA Cardiol. 2017;2(7):715-716. doi:10.1001/jamacardio.2017.0983
Editorial

Lesion-Specific Ischemia With Noninvasive Computed Tomographic Angiography: Superior to Conventional Stress Testing?

Abstract Full Text
JAMA Cardiol. 2017;2(7):717-719. doi:10.1001/jamacardio.2017.1315

New Blood Pressure–Lowering Targets—Finding Clarity

Abstract Full Text
JAMA Cardiol. 2017;2(7):719-720. doi:10.1001/jamacardio.2017.1422

Determinants, Associations, Consequences, and Prevention of Readmissions After Transcatheter Aortic Valve Replacement

Abstract Full Text
JAMA Cardiol. 2017;2(7):721-722. doi:10.1001/jamacardio.2017.1650
Review

Diagnostic Accuracy of Computed Tomography–Derived Fractional Flow Reserve: A Systematic Review

Abstract Full Text
has active quiz
JAMA Cardiol. 2017;2(7):803-810. doi:10.1001/jamacardio.2017.1314

This systematic review evaluates the accuracy of computed tomography–derived fractional flow reserve in diagnosis for patients with myocardial ischemia.

JAMA Cardiology Clinical Evidence Synopsis

Efficacy of Catheter Ablation for Nonparoxysmal Atrial Fibrillation

Abstract Full Text
JAMA Cardiol. 2017;2(7):812-813. doi:10.1001/jamacardio.2017.0901

This study examines whether catheter ablation is better than antiarrhythmic drugs for the prevention of nonparoxysmal atrial fibrillation.

Comment & Response

Potential of Oncocardiology

Abstract Full Text
JAMA Cardiol. 2017;2(7):817. doi:10.1001/jamacardio.2017.0116

Potential of Oncocardiology

Abstract Full Text
JAMA Cardiol. 2017;2(7):817-818. doi:10.1001/jamacardio.2017.0119

Potential of Oncocardiology—Reply

Abstract Full Text
JAMA Cardiol. 2017;2(7):818. doi:10.1001/jamacardio.2017.0122

Let Us Not Forget the Long-term Safety Concerns of Sacubitril/Valsartan

Abstract Full Text
JAMA Cardiol. 2017;2(7):818-819. doi:10.1001/jamacardio.2017.0423

Regarding Twitter as a Potential Data Source for Cardiovascular Disease Research

Abstract Full Text
JAMA Cardiol. 2017;2(7):819-820. doi:10.1001/jamacardio.2017.0194

Let Us Not Forget the Long-term Safety Concerns of Sacubitril/Valsartan—Reply

Abstract Full Text
JAMA Cardiol. 2017;2(7):819. doi:10.1001/jamacardio.2017.0426

Microangiopathy, Arterial Stiffness, and Risk Stratification in Patients With Type 2 Diabetes

Abstract Full Text
JAMA Cardiol. 2017;2(7):820-821. doi:10.1001/jamacardio.2017.0159

Regarding Twitter as a Potential Data Source for Cardiovascular Disease Research—Reply

Abstract Full Text
JAMA Cardiol. 2017;2(7):820. doi:10.1001/jamacardio.2017.0197

Microangiopathy, Arterial Stiffness, and Risk Stratification in Patients With Type 2 Diabetes—Reply

Abstract Full Text
JAMA Cardiol. 2017;2(7):821. doi:10.1001/jamacardio.2017.0164
Editor's Note

The Balance Between Access and Quality in Transcatheter Valve Therapies

Abstract Full Text
free access
JAMA Cardiol. 2017;2(7):741. doi:10.1001/jamacardio.2017.1651

Claims Data to Ascertain Clinical Events: Lost in Translation

Abstract Full Text
free access
JAMA Cardiol. 2017;2(7):758. doi:10.1001/jamacardio.2017.1580

One-Year Follow-up of the European Ambulance Acute Coronary Syndrome Angiography Trial

Abstract Full Text
free access
JAMA Cardiol. 2017;2(7):797. doi:10.1001/jamacardio.2016.5976

The Changing Paradigm for Assessment of Ischemic Coronary Artery Disease

Abstract Full Text
free access
JAMA Cardiol. 2017;2(7):811. doi:10.1001/jamacardio.2017.1316
Correction

Correction of 95% CI in Table

Abstract Full Text
free access
JAMA Cardiol. 2017;2(7):821. doi:10.1001/jamacardio.2017.1575
JAMA Cardiology Patient Page

I Do Not Have Heart Disease—Should I Be Taking Aspirin?

Abstract Full Text
free access
JAMA Cardiol. 2017;2(7):824. doi:10.1001/jamacardio.2017.0294
JAMA Cardiology Masthead

JAMA Cardiology

Abstract Full Text
free access
JAMA Cardiol. 2017;2(7):710. doi:10.1001/jamacardio.2016.3655
×